Share this video  

ASCO 2019 | EV-201: enfortumab vedotin for bladder cancer

Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, tells about the EV-201 bladder cancer study (NCT03219333) which investigated enfortumab vedotin for patients with locally advanced or metastatic urothelial bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.